Medindia

X

New Findings Prompt Reappraisal of Hypertension Guidelines

by Rajshri on  November 2, 2009 at 8:23 PM Hypertension News   - G J E 4
 New Findings Prompt Reappraisal of Hypertension Guidelines
The official European guidelines on the management and treatment of hypertension have been released by a Task Force of the European Society of Hypertension. The guidelines are an update of those published in 2007, and will be published in the November issue of the Journal of Hypertension.
Advertisement

The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

Advertisement
In the two years since the publication of the 2007 guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC), research on hypertension has actively been pursued and the results of new important studies (including several large randomized trials of antihypertensive therapy) have been published. The aim of the Task Force was to address these results in order to assess their contribution to our expanding knowledge of hypertension.

While some of the studies have reinforced the evidence on which the recommendations of the 2007 ESH/ESC guidelines were based, others have widened the information available in 2007, modifying some of the previous concepts, and suggesting that new evidence-based recommendations could be appropriate. The guidelines draw new conclusions on how to assess hypertension-related organ damage, when to initiate antihypertensive therapy, what the blood pressure target should be in the elderly, the diabetic and the high risk patient, how to choose among available antihypertensive agents and how to combine them.

In addition, the Task Force has made suggestions for further research and trials that need to be carried out, stressing the importance of evidence as a basis on which decisions on hypertension management should be made. The results of further research, they state, might be a useful step toward the preparation of a third version of the guidelines in the future.

About The Journal of Hypertension
The journal consistently attracts the most important and highly innovative papers from the current research; our commitment to rapid publication ensures that these are published in the fastest time possible. In addition to primary papers from world-renowned experts, the Journal contains authoritative reviews that summarize and evaluate the most significant recent developments. Also included are special reports, original short papers containing innovative and time-sensitive information.

About Lippincott Williams & Wilkins
Lippincott Williams & Wilkins (LWW) is a leading international publisher for healthcare professionals and students with nearly 300 periodicals and 1,500 books in more than 100 disciplines publishing under the LWW brand, as well as content-based sites and online corporate and customer services.

LWW is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health and pharmacy. Major brands include traditional publishers of medical and drug reference tools and textbooks, such as Lippincott Williams & Wilkins and Facts & Comparisons®; and electronic information providers, such as Ovid®, UpToDate®, Medi-Span® and ProVation® Medical.

Wolters Kluwer Health is part of Wolters Kluwer, a leading global information services and publishing company. The company provides products and services for professionals in the health, tax, accounting, corporate, financial services, legal, and regulatory sectors. Wolters Kluwer had 2008 annual revenues of €3.4 billion ($4.9 billion), employs approximately 20,000 people worldwide, and maintains operations in over 35 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Amsterdam, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.



Source: Newswise
RAS
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All